As the UK makes its way out of the EU through Brexit, Malta’s pharmacies have started to feel the devastating impact as many popular medicines are running short. Considered a third country by the EU, the UK is no longer part of the single market for pharmaceuticals. Medicines for migraine Solpadeine and eye drop products Timolol, Cosopt and Travatan have run out with other medicines which are not easy to replace, such as Thyroxine, will soon be absent from pharmacy shelves.
Chairman of the pharmaceutical division of the Chamber of Small and Medium Enterprises Mario Debono revealed this information, stating that this was just the initial wave of medicines to experience the low-stock and/or absence. Panadol Advance, Rennie and Feimax are also experiencing the same treatment. Many Maltese have been accustomed to the products which have unique formulations but are now expected to be unavailable.
Debono expressed how this places Malta in a difficult position as whilst these may be made available from other sources, an increase in costs is very likely. Ireland could be an alternative source, but even this small country could face stock shortages as the UK keeps it to itself.
The pressure is being felt at the governmental level as well as alternative sources are not easily found. EU prices were higher than the UK’s where the market was driven by supply and demand. With importation from the UK meaning re-registering, the cost could shoot up to around €48,000 – a price a small market does not find viable.
Debono himself stated that the EU should have ‘brokered a special arrangement and presented the argument that the EU cannot push us into a worse situation in terms of price and availability. Health is a matter of national – not EU – competence.’ Debono also suggests Malta do like Cyprus, which is to go for national registration of products from the UK.
#MaltaDaily
Photo Source: Czech universities